BETA: Please send your feedback!
NewLink Genetics
NLNK:NAS
Biotechnology
$0
SMALL cap
$1.50
(0.13%)
-0.08%
since start of 2019
-1.46
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
-
CF
-
PP
-
WC
-
DP
-
CH
-
ES
-
WS
-
CG
-
EP
-
CM
-
FL
-
GD
- —
- 1
- 2
- 3
- 4
- 5
About
Biotechnology
Founded 1999
NewLink Genetics Corp. is a clinical stage immuno-oncology company, which focuses on discovering, developing and commercializing novel immunotherapeutic products to improve cancer treatment options for patients and physicians. Its portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. The company's products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189 and IDO Pathway Inhibitors. NewLink Genetics was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Ames, IA.
website
Headquarters
Executives
| Name | Title | Gender |
| John B. Henneman, III | Chief Financial Officer, Secretary & Executive VP | Male |
| Thomas P. Monath, MD | Chief Scientific Officer | Male |
| Charles J. Link, MD | Chairman, Chief Executive & Scientific Officer | Male |
| Nicholas N. Vahanian, MD, MBA | President, Director & Chief Medical Officer | Male |
| Eugene P. Kennedy | Vice President-Clinical & Medical Affairs | Male |
| Eugene Sackett | Vice President-Human Resources | Male |
Mindful Investing Summary
- —
- 1
- 2
- 3
- 4
- 5
-
Carbon Footprint — N/A
-
Pollution Prevention — N/A
-
Water Conservation — N/A
-
Data & Privacy Protection — N/A
-
Consumer Health, Wellness & Safety — N/A
-
Employee Ownership, Satisfaction, Benefits & Pay — N/A
-
Workplace Health and Safety — N/A
-
Integrity of Corporate Governance — N/A
-
Ethical Practices — N/A
-
Usage of Conflict Materials — N/A
-
Forced Labor — N/A
-
Diversity of Corporate Leadership 2
NewLink Genetics - Competitors and Related Companies
How NewLink Genetics stacks up to its peers in the Biotechnology industry or with competing business segments.
NewLink Genetics
NLNK:NAS
Biotechnology
$0
SMALL cap
$1.50
(0.13%)
-0.08%
since start of 2019
-1.46
SIGA Technologies
SIGA:NAS
Pharmaceuticals: Other
$444.95mm
SMALL cap
$5.49
(0.10%)
-0.27%
since start of 2019
1.00
Sinovac Biotech
SVA:NAS
Biotechnology
$460.25mm
SMALL cap
$6.47
(0.00%)
-0.07%
since start of 2019
18.50
Sarepta Therapeutics
SRPT:NAS
Biotechnology
$6.43bn
MID cap
$86.50
(0.73%)
-0.19%
since start of 2019
-10.80
Eli Lilly
LLY:NYS
Pharmaceuticals: Major
$104.18bn
MEGA cap
$107.91
(-0.73%)
-0.06%
since start of 2019
25.65
Johnson & Johnson
JNJ:NYS
Pharmaceuticals: Major
$337.87bn
MEGA cap
$128.02
(0.32%)
0.00%
since start of 2019
—